Clinton Group Inc. raised its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 18.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,041 shares of the biopharmaceutical company’s stock after buying an additional 4,927 shares during the period. Clinton Group Inc. owned about 0.08% of Emergent Biosolutions worth $1,010,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in EBS. The Manufacturers Life Insurance Company acquired a new position in shares of Emergent Biosolutions during the third quarter worth $20,471,000. Analytic Investors LLC purchased a new position in Emergent Biosolutions during the third quarter valued at approximately $773,000. Two Sigma Advisers LP increased its position in Emergent Biosolutions by 10.9% in the third quarter. Two Sigma Advisers LP now owns 160,090 shares of the biopharmaceutical company’s stock valued at $5,048,000 after buying an additional 15,700 shares during the last quarter. SECOR Capital Advisors LP increased its position in Emergent Biosolutions by 20.2% in the third quarter. SECOR Capital Advisors LP now owns 64,797 shares of the biopharmaceutical company’s stock valued at $2,043,000 after buying an additional 10,906 shares during the last quarter. Finally, Piermont Capital Management Inc. increased its position in Emergent Biosolutions by 9.3% in the third quarter. Piermont Capital Management Inc. now owns 35,594 shares of the biopharmaceutical company’s stock valued at $1,122,000 after buying an additional 3,020 shares during the last quarter. 89.67% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Emergent Biosolutions, Inc. (NYSE:EBS) traded down 1.43% during midday trading on Friday, hitting $29.71. The company had a trading volume of 311,475 shares. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 28.13 and a beta of 1.02. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $44.38. The company’s 50-day moving average price is $31.03 and its 200 day moving average price is $29.60.
Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.32. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. The firm had revenue of $142.91 million for the quarter, compared to analysts’ expectations of $112.30 million. During the same quarter last year, the firm earned $0.93 EPS. The company’s quarterly revenue was down 9.8% compared to the same quarter last year. Equities research analysts predict that Emergent Biosolutions, Inc. will post $1.06 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first reported by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another website, it was illegally copied and reposted in violation of US and international trademark & copyright law. The original version of this article can be accessed at http://sleekmoney.com/emergent-biosolutions-inc-ebs-stake-boosted-by-clinton-group-inc/1655311.html.
Several research firms have recently commented on EBS. Chardan Capital set a $47.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a research report on Saturday, December 10th. Cowen and Company reaffirmed a “hold” rating on shares of Emergent Biosolutions in a research report on Monday, January 9th. Finally, Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $39.40.
In other Emergent Biosolutions news, insider Daniel Abdun-Nabi sold 28,240 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $31.28, for a total transaction of $883,347.20. Following the transaction, the insider now owns 172,945 shares of the company’s stock, valued at approximately $5,409,719.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronald Richard sold 5,900 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $34.09, for a total transaction of $201,131.00. Following the transaction, the director now directly owns 19,870 shares in the company, valued at approximately $677,368.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,002 shares of company stock worth $1,913,955. Insiders own 17.20% of the company’s stock.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/emergent-biosolutions-inc-ebs-stake-boosted-by-clinton-group-inc/1655311.html
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.